Pfizer says earliest US filing for Covid-19 vaccine would be late November

By Manas Mishra and Michael Erman (Reuters) - Pfizer Inc said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year. That timeline makes it unlikely, however, that a vaccine will be available before the U.

S. election, as President Donald Trump has promised. Pfizer, which is developing the vaccine with German partner BioNTech <22UAy.F>, said that it may confirm if the vaccine.

This article is no longer available in our repository.

There could be multiple reasons for this.